STALEVO 100 Rx
Generic Name and Formulations:
Carbidopa 25mg, levodopa 100mg, entacapone 200mg; tabs.
Novartis Pharmaceuticals Corp
Indications for STALEVO 100:
In idiopathic Parkinson's disease: to substitute for equivalent doses of previously-administered carbidopa/ levodopa and entacapone; and to replace immediate-release carbidopa and levodopa in patients with end-of-dose "wearing-off" symptoms who are taking levodopa up to 600mg/day without having dyskinesias.
Swallow whole; max one tablet per dosing interval. Previously on carbidopa/levodopa and entacapone: substitute on a mg/mg basis. Stalevo 50, 75, 100, 125, 150: max 8 tabs/day; Stalevo 200: max 6 tabs/day. Others: individualize; see literature. Avoid abrupt cessation.
During or within 2 weeks of nonselective MAOIs (eg, phenelzine). Narrow-angle glaucoma. Undiagnosed skin lesions. History of melanoma.
Severe cardiovascular or pulmonary disease. Asthma. Dyskinesias. Renal, hepatic, or endocrine disorders. Biliary obstruction. Orthostatic hypotension. History of peptic ulcer or MI with residual arrhythmias. Suicidal tendencies. Psychosis. Chronic wide-angle glaucoma. Monitor cardiovascular, hematopoietic, renal and hepatic function, IOP. May stain body fluids. Elderly (>75yrs). Pregnancy (Cat.C). Nursing mothers.
Dopa-decarboxylase inhibitor + dopamine precursor + COMT inhibitor.
See Contraindications. Orthostatic hypotension with selegiline, antihypertensives. Antagonized by isoniazid, dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone), phenytoin, papaverine; possibly iron, high protein diets, excessive gastric acidity. Hypertension, dyskinesias with tricyclics. Metoclopramide. May cause false (+) urinary ketone test or false (–) urinary glucose (glucose oxidase) test. Potentiates CNS depression with alcohol, other CNS depressants. Chelates iron. Cardiac effects with drugs metabolized by COMT (eg, epinephrine, isoproterenol, dopamine, dobutamine, methyldopa, apomorphine, bitolterol). Caution with drugs that interfere with biliary excretion, glucuronidation, or intestinal beta-glucuronidase (eg, probenecid, cholestyramine, erythromycin, rifampicin, ampicillin, chloramphenicol).
Dyskinesias, GI upset (esp. diarrhea), CNS disturbances (eg, hallucinations, confusion, depression, psychosis, dizziness, headache, abnormal dreams, insomnia, somnolence), hypo- or hypertension, syncope, dyspnea, on-off phenomena, blepharospasm (may indicate excess dose), urine discoloration, lab abnormalities, rhabdomyolysis, neuroleptic malignant syndrome, hyperpyrexia and confusion upon withdrawal.
Tabs 50, 100, 150—100, 250; 75, 125, 200—100
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency